HardwareSydney, AustraliaFounded 2013· One of 1708 Hardware companies tracked by AMPulse
Inventia Life Science develops world-leading bioprinting technology for advanced medical research, enabling 3D cell culture and tissue engineering applications.
RASTRUM 3D Bioprinter, RASTRUM Allegro (2nd generation), LIGO Surgical Tool for in-situ tissue reconstruction, Bioink reagents and consumables
Technological Advantage
Proprietary drop-on-demand bioprinting technology that creates complex 3D tissue models faster and more consistently than manual methods
Differentiation
Value Proposition
Automates 3D cell culture with reproducible, scalable bioprinting technology that accelerates drug discovery and tissue engineering research.
How They Differentiate
Automation-first approach with high throughput capabilities versus competitors manual bioprinting systems
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, biotechnology laboratories
Industry Verticals
Life Sciences, Pharmaceutical Research, Biotechnology, Tissue Engineering
Competitors
CELLINK/Cytiva, Organovo, Aspect Biosystems
Growth & Milestones
Growth Metrics
$15M ARR as of September 2025; 65 employees across 3 continents (Oceania, North America, Europe); 4 of top 10 global pharma companies as customers
Major Milestones
2013: Founded in Sydney; 2017: First institutional funding from Blackbird Ventures; 2019: Series A funding, RASTRUM platform development; 2021: AU$35M Series B led by Blackbird, US market entry; 2022: HESTA investment, MSD partnership announced; 2023: India market entry via Biotron Healthcare; 2025: RASTRUM Allegro launch, reached $15M ARR
Notable Customers
MSD/Merck (first pharma in Europe to use RASTRUM), Multiple top 10 global pharmaceutical companies, Leading research institutions worldwide, Biotron Healthcare (India distribution), Three leading US pharmaceutical companies
Inventia Life Science occupies a specific niche in bioprinting: automating 3D cell culture to improve reproducibility and throughput over manual methods. Its RASTRUM platform uses proprietary drop-on-demand technology to deposit cells and bioinks into complex tissue models, aiming to accelerate drug discovery and reduce reliance on animal testing. The company positions itself as an automation-first alternative to competitors like CELLINK/Cytiva and Organovo, whose systems often require more hands-on operation.
The core product line includes the RASTRUM 3D Bioprinter and its second-generation RASTRUM Allegro, launched in 2025. Inventia also offers the LIGO Surgical Tool for in-situ tissue reconstruction and a range of bioink reagents and consumables. The platform is designed for high-throughput workflows, enabling researchers to produce consistent 3D tissue models faster than with manual pipetting or earlier bioprinting approaches.
Inventia's target customers are research institutions, pharmaceutical companies, and biotechnology laboratories. Notable customers include MSD/Merck, which was the first pharmaceutical company in Europe to adopt the RASTRUM platform, and multiple top-10 global pharmaceutical firms. As of September 2025, the company reported $15 million in annual recurring revenue and 65 employees across Oceania, North America, and Europe. Key investors include Blackbird Ventures, Skip Capital, In-Q-Tel, AirTree, and HESTA.
The company's strategic moat rests on its automation-first design and proprietary drop-on-demand bioprinting IP, which together aim to deliver reproducibility at scale. A key open question is whether the platform can maintain its throughput advantage as competitors develop similar automation capabilities. Inventia's ability to expand beyond pharmaceutical R&D into clinical applications, such as in-situ tissue reconstruction with the LIGO tool, will also determine its long-term market position.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights